King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) — For the past four decades, the Cyclotron and Radiopharmaceuticals Department at King Faisal Specialist Hospital and Research Centre (KFSH&RC) has been addressing the needs of local and regional medical centers for radiopharmaceuticals used in diagnosing and treating various specialized diseases. Since its establishment, the department has […]

King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom_01

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) — For the past four decades, the Cyclotron and Radiopharmaceuticals Department at King Faisal Specialist Hospital and Research Centre (KFSH&RC) has been addressing the needs of local and regional medical centers for radiopharmaceuticals used in diagnosing and treating various specialized diseases.

Since its establishment, the department has produced over 25 types of radiopharmaceuticals with a production capacity exceeding 600,000 radiopharmaceutical preparations. The department continues to provide its products to over 50 specialized Saudi medical centers, aiming to achieve self-sufficiency in the field of radiopharmaceuticals in the Kingdom of Saudi Arabia.

King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom_02

During the Global Health Exhibition that commenced yesterday in the capital city of Riyadh, where KFSH&RC participates as a strategic health partner, the hospital highlights the department’s pioneering role in nuclear medicine. This includes enhancing the capabilities of healthcare providers in both research and education, as well as ensuring the quality in the production and distribution of radiopharmaceuticals to hospitals across the Kingdom and beyond.

The Cyclotron and Radiopharmaceuticals Department aspires to become a diagnostic and molecular imaging center and the first facility for Technetium-99m (Tc-99m) generators in the Kingdom. It conducts research to develop high-quality radiopharmaceuticals for KFSH&RC and other hospitals throughout the Kingdom to meet all healthcare needs of patients. The department adheres to high-quality standards for automated quality control and assurance while striving to advance cyclotron technology, precise radiopharmaceutical manufacturing, and the development of radiopharmaceuticals used in positron emission tomography/computed tomography (PET/CT).

The department significantly emphasizes quality, with an integrated product quality control and management unit, manufacturing materials following Good Manufacturing Practices (GMP), the Saudi Food and Drug Authority (SFDA) standards, and ISO 9001 international quality management system standards. All operational processes are subjected to rigorous monitoring for the periodic evaluation of materials, ensuring their continuous suitability. This approach has led to a remarkable customer satisfaction rate exceeding 95%.

KFSH&RC is globally recognized for providing specialized healthcare and is a leader in innovation, advanced medical research, and medical education. The institution actively seeks to develop medical technologies and enhance the standard of healthcare worldwide, partnering with leading local, regional, and international organizations to deliver world-class services in clinical, research, and educational domains.

Contact information:
kfshrc@mcsaatchi.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/ad78d2ea-0d15-45ae-a3bd-cd25f7bf7ab9

https://www.globenewswire.com/NewsRoom/AttachmentNg/1d1f90e9-3a44-43cf-8812-af6760e2d0b2

GlobeNewswire Distribution ID 8968426

Total
0
Shares
Previous Article

Zoom AI Companion hits one million meeting summaries milestone

Next Article

‫”التخصصي” يسعى لتحقيق الاكتفاء الذاتي من المستحضرات الصيدلانية المشعة في المملكة

Related Posts

‫ تعيين شين تيدجراتي، الرئيس التنفيذي السابق في شركة هانيويل، رئيسًا لمجلس إدارة شركة VS Partners

هونغ كونغ، 24 يناير 2022 / PRNewswire / — قرّرت شركة VS Partners في يناير 2022 تعيين السيد/ شين تيدجراتي رئيسًا لمجلس إدارتها، وذلك بعد تقاعده من منصبه السابق كرئيس ومدير تنفيذي لعمليات التوسع في المناطق ذات النمو المرتفع عالميًا لدى شركة هانيويل (“ Honeywell “) (رمز التداول في بورصة نيويورك: HON ). وتُعدّ شركة […]

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA) ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with […]